FDA approves 7.2 mg Wegovy boosting weight loss 21%; Indian generics cut prices to $14/month

The FDA has authorized a high-dose Wegovy injection at 7.2 mg, resulting in an average 21% body weight loss over 72 weeks, tripling the prior approved dose. Concurrently, Indian pharmaceutical firms launched generic semaglutide drugs, including versions of Ozempic and Wegovy, priced roughly 70% lower at around $14 per month, following patent expiration. These dual developments could transform the global obesity treatment landscape by expanding patient access and intensifying competition, prompting Novo Nordisk and peers to adjust pricing and innovation strategies.

The FDA has approved a higher 7.2 mg dose of Wegovy, known as Wegovy HD, which delivers an average body weight loss of 21 percent over 72 weeks, according to The Independent and Fox News Health. This triple-strength dose aims to provide enhanced long-term weight management for adults with obesity or overweight conditions, marking a notable advance in treatment options.

Clinical trial data supporting the FDA’s decision demonstrated significantly improved weight loss compared to previous doses, with Wegovy HD being the fourth drug approved under the FDA’s National Priority Voucher pilot program, STAT News reports. Despite outperforming the standard Wegovy dose, the higher-dose formulation still trails competing treatments like Eli Lilly’s Zepbound in weight loss efficacy.

Concurrently, Indian pharmaceutical firms including Dr. Reddy’s, Glenmark, and Sun Pharma launched generic versions of semaglutide drugs Ozempic and Wegovy immediately after the expiration of Novo Nordisk’s patents, as detailed by Lopez Doriga Digital. These generics, priced around $14 per month, represent roughly a 70% reduction from branded versions and could dramatically increase access to these therapies in India’s large diabetes and obesity patient populations.

The introduction of low-cost generics in India is expected to intensify competition for Novo Nordisk, the Danish manufacturer of Wegovy and Ozempic, which has secured patent protections but attempts to block generic entrants have been contested, per The National and National Post. Market analysts foresee growing challenges for brand leaders as generics expand availability in emerging markets.

Looking ahead, global obesity treatment landscapes are likely to evolve with this FDA approval enabling broader therapeutic options and Indian generics driving affordability. Observers will monitor how Novo Nordisk responds to rising competition and whether higher-dose Wegovy's clinical benefits translate into wider adoption among patients struggling with weight management.